Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Conduit Pharmaceuticals Inc. - Common Stock (NQ: CDT )

0.1337 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,043
Open 0.1337
Bid (Size) 0.1320 (30)
Ask (Size) 0.1337 (34)
Prev. Close 0.1337
Today's Range 0.1337 - 0.1337
52wk Range 0.1126 - 10.40
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Performance

YTD
-97.15%
-97.15%
1 Month
-17.06%
-17.06%
3 Month
-90.84%
-90.84%
6 Month
-96.12%
-96.12%
1 Year
-98.71%
-98.71%

More News

Read More
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Conduit Pharmaceuticals
Via GlobeNewswire
Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?
Via InvestorPlace
Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024
Via InvestorPlace
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
From Conduit Pharmaceuticals
Via GlobeNewswire
S&P 500 Gains 1%; US Jobless Claims Fall To 230,000
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
From Conduit Pharmaceuticals
Via GlobeNewswire
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
Via Benzinga
Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What Happened With Conduit Pharmaceuticals (CDT) Stock Today?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?
Via InvestorPlace
Why Is Autonomix Medical (AMIX) Stock Down 17% Today?
Via InvestorPlace
Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
From Conduit Pharmaceuticals
Via GlobeNewswire
Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Conduit Pharmaceuticals to Join Russell 3000® Index
From Conduit Pharmaceuticals
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback